Surprise, Skepticism And Scorn: Reaction To Rumored Haleon Interest In Sanofi CHC
Executive Summary
Analysts share their thoughts on reports that Haleon is interested in acquiring Sanofi Consumer Healthcare to enhance its market leading position.
You may also be interested in...
Sanofi Consumer Healthcare Reaches 'Next Level Of Autonomy'
The integration of core business functions at Sanofi Consumer Healthcare represents the “next level of autonomy” for the business, according to group CFO Jean-Baptiste Chasseloup de Chatillon. “As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more compelling.” The move came as Sanofi Consumer Healthcare reported a strong end to 2022, with Q4 sales up by 6.6% at constant exchange rates to €1.22bn.
Euro Q4 Consumer Health Earnings Preview: Sanofi, Bayer, Reckitt And Haleon
Major Europe-based consumer health players Sanofi Bayer, Reckitt and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q4 2022 results over the coming weeks.
Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.